Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS)
ConditionT Cell Lymphoma
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age20-85
SponsorWon Seog Kim
About this trial
Induction treatment (every 3 weeks, total 6 cycles)
* Azacitidine D-2, -1, 1 (level 1: 50mg/m2, level 2: 75mg/m2, level 3: 100mg/m2, level 4: 125mg/m2) * Cyclophosphamide 750mg/m2 d1 * Doxorubicin 50 mg/m2 d1 * Vincristine 1.4 mg/m2 (Max: 2 mg) d1 * Prednisolone 100mg PO d1-5 Maintenance treatment (every 4 weeks, total 12 cycles) * Azacitidine 75mg/m2 d1-5
Eligibility criteria
Qualifiers
Angioimmunoblastic T-cell lymphoma
Follicular helper T-cell lymphoma
Peripheral T-cell lymphoma with follicular helper T-cell type
20 to 85 years of age at diagnosis
Disqualifiers
Other subtypes of non-Hodgkin's lymphoma
History of chemotherapy for Hodgkin's or other non-Hodgkin's lymphoma in the last 5 years
History of active cancer diagnosed within the last 3 years (with the exception of completely resected non-melanoma skin cancer, papillary thyroid cancer, carcinoma in situ of cervical cancer or breast cancer, and localized prostate cancer)
Uncontrolled hepatitis B (with the exception of asymptomatic HBsAg-positive or anti-HBcAb-positive cases receiving antiviral prophylaxis such as entecavir or tenofovir)
Trial design
Treatments tested in this trial
- ACHOP
Treatment groups
41 Participants
are divided into 1 treatment groupSponsors and collaborators
Won Seog Kim
Lead sponsor
Samsung Medical Center
Sponsor institution
Source ClinicalTrials.gov